- KW-2449
-
- $30.00 / 5mg
-
2025-11-11
- CAS:1000669-72-6
- Min. Order:
- Purity: 99.89%
- Supply Ability: 10g
|
| | [4-[2-(1H-Indazol-3-yl)ethenyl]phenyl]-1-piperazinylmethanone Basic information |
| Product Name: | [4-[2-(1H-Indazol-3-yl)ethenyl]phenyl]-1-piperazinylmethanone | | Synonyms: | [4-[2-(1H-Indazol-3-yl)ethenyl]phenyl]-1-piperazinylmethanone;KW 2449;(E)-(4-(2-(1H-indazol-3-yl)vinyl)phenyl)(piperazin-1-yl)methanone;KW2449(E)-(4-(2-(1H-indazol-3-yl)vinyl)phenyl)(piperazin-1-yl)methanonehydrochloride;KW-2449;KW 2449; KW2449;[4-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone;KW-2449 100MG;{4-[(E)-2-(1H-Indazol-3-yl)vinyl]phenyl}(1-piperazinyl)methanone | | CAS: | 1000669-72-6 | | MF: | C20H20N4O | | MW: | 332.4 | | EINECS: | | | Product Categories: | Inhibitors;Inhibitor | | Mol File: | 1000669-72-6.mol | ![[4-[2-(1H-Indazol-3-yl)ethenyl]phenyl]-1-piperazinylmethanone Structure](CAS/GIF/1000669-72-6.gif) |
| | [4-[2-(1H-Indazol-3-yl)ethenyl]phenyl]-1-piperazinylmethanone Chemical Properties |
| Boiling point | 604.1±55.0 °C(Predicted) | | density | 1.28 | | storage temp. | -20°C | | solubility | Soluble in DMSO (>25 mg/ml) | | form | solid | | pka | 13.76±0.40(Predicted) | | color | Pale yellow | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month. |
| | [4-[2-(1H-Indazol-3-yl)ethenyl]phenyl]-1-piperazinylmethanone Usage And Synthesis |
| Description | KW-2449 is a potent multikinase inhibitor (IC50’s: FLT3 = 7 nM, FGFR1 = 36 nM, Abl = 14 nM, Abl-T315 = 4 nM) with anti-leukemic effects.1,2,3 | | Uses | KW-2449 is a multi-targeted kinase inhibitor of FLT3, ABL, ABLT315I and Aurora kinase with IC50s of 6.6, 14, 4 and 48 nM, respectively. | | Definition | ChEBI: [4-[2-(1H-indazol-3-yl)ethenyl]phenyl]-(1-piperazinyl)methanone is a member of indazoles. | | in vivo | Oral administration of KW-2449 shows dose-dependent and significant tumor growth inhibition in FLT3-mutated xenograft model with minimum bone marrow suppression. In FLT3 wild-type human leukemia, it induces the reduction of phosphorylated histone H3, G2/M arrest, and apoptosis. In imatinib-resistant leukemia, KW-2449 contributes to release of the resistance by the simultaneous down-regulation of BCR/ABL and Aurora kinases. Furthermore, the antiproliferative activity of KW-2449 is confirmed in primary samples from AML and imatinib-resistant patients. The inhibitory activity of KW-2449 is not affected by the presence of human plasma protein, such as α1-acid glycoprotein[1]. | | target | FLT3 | | IC 50 | Abl: 4 nM (IC50); ABL-T315I: 14 nM (IC50); FGFR1: 36 nM (IC50); Aurora A: 48 nM (IC50); FLT3/D835Y: 1 nM (IC50); FLT3: 6.6 nM (IC50); JAK2: 150 nM (IC50); SRC: 400 nM (IC50); PDFGRα: 1700 nM (IC50) | | References | [1] Y. SHIOTSU. KW-2449, a Novel Multi-Kinase Inhibitor Against FLT3, Abl, FGFR1 and Aurora, Suppresses the Growth of AML Both In Vitro and In Vivo .[J]. Blood, 2007, 110 1: 1832-1832. DOI:10.1182/blood.v110.11.1832.1832
[2] KW-2449, a Novel Multi-Kinase Inhibitor, suppresses the growth of leukemia cells with FLTY3 mutations or T315l-mutated BCR/ABL translocation
[3] KEITH W PRATZ. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response.[J]. Blood, 2009, 113 17: 3938-3946. DOI:10.1182/blood-2008-09-177030 |
| | [4-[2-(1H-Indazol-3-yl)ethenyl]phenyl]-1-piperazinylmethanone Preparation Products And Raw materials |
|